A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model

Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D. Nelson, Tara A. Russell, Sarah M. Dry, Yunfeng Li, Mark A. Eckardt, Arun S. SinghSant Chawla, Fuminori Kanaya, Fritz C. Eilber, Shree Ram Singh, Ming Zhao, Robert M. Hoffman

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Fingerprint Dive into the research topics of 'A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences